AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis
AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. Alexion focuses on finding medications for rare diseases and has an ongoing clinical trial for Ultomoris (Ravulizumab) to treat the rare disease - Amyotrophic Lateral Sclerosis (ALS).
ALS is a neurodegenerative neuromuscular disease that can slowly weaken muscles and impair physical function. A progressive loss of moto...
